Does FTC Privacy Lawsuit Change The Bull Case For Hims & Hers Stock (HIMS)?

• Hims & Hers Health is facing an FTC lawsuit and multiple securities class actions over alleged misuse of consumer health data and disputed billing and cancellation practices, with claims that prior disclosures to customers and investors were materially misleading.
• The legal focus on how Hims & Hers Health handled data privacy, consultations and subscription charges raises direct questions about customer trust, regulatory costs and the durability of its telehealth business model.
• We will look at how the growth-focused investment narrative for Hims & Hers Health is tested by alleged misuse of sensitive customer health data.

Spot opportunities across telehealth and consumer health by scanning a curated set of 16 high quality undiscovered gems that share some of Hims & Hers Health's growth ambitions without attracting the same level of legal attention.

Hims & Hers Health Investment Narrative Recap

To own Hims & Hers Health, you need to believe its consumer telehealth model can keep drawing in users who want convenient access to treatments across sexual health, weight loss and hormone care, even as regulations tighten. The key near term catalyst is continued traction in these categories and subscriptions, which ties directly to execution on clinical quality, retention and marketing efficiency.

The biggest near term risk is the cluster of FTC and securities lawsuits around data sharing, billing and consultations. These relate directly to trust, potential fines and operating friction. If disclosures, consent flows and billing practices need a redesign, short term growth, costs and international expansion plans could all feel pressure.

The FTC complaint and the series of securities class actions are the most relevant developments right now. Allegations that Hims & Hers Health mishandled sensitive health data and charged for prescriptions before proper consultation sit uncomfortably beside a model built on personalization, AI tools and ongoing digital engagement. That gap is exactly what regulators are questioning.

These cases also intersect with the firm’s push into categories like weight loss, sexual health subscriptions and international markets. Any tighter rules around data use or telehealth prescribing could affect how quickly new offerings roll out or how aggressively the platform can market them. For you, the question is whether management can adjust operations fast enough to keep the growth story intact while absorbing higher compliance expectations.

Hims & Hers Health's current analyst storyline points to revenues of US$4.6b and earnings of US$241.0m by 2029, based on revenue rising 21.6% a year and a shift from today’s earnings loss of US$142.0m to that 2029 forecast, which is an earnings increase of about US$383.0m.

Discover why Hims & Hers Health's fair value indicates a 12% potential upside to its current price, a gap that could narrow quickly.

Exploring Other Perspectives

You are seeing how fragile the Hims & Hers Health story looks if data privacy risk becomes the main lens. The most cautious analysts were already working with lower expectations, penciling in about US$4.3b of revenue and US$218.1m of earnings by 2029. This lawsuit cluster could push those already downbeat views even further. Treat it as a prompt to explore several competing narratives before deciding what feels reasonable to you.

Explore 17 other Hims & Hers Health fair value estimates, including one that suggests as much as 10% downside from the current price.

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Hims & Hers Health research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
• See our latest analysis for Hims & Hers Health. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake. This makes it easy to evaluate Hims & Hers Health's overall financial health at a glance.

Looking for more investment ideas beyond Hims & Hers Health?

If the Hims & Hers Health story has you thinking more broadly about where to put fresh capital to work, it can help to scan for other businesses that fit your risk tolerance, income needs and time horizon using the Simply Wall St Screener.

• Prefer stability and balance sheet strength over drama and lawsuits? Start by checking a list of solid balance sheet and fundamentals (22 results) that can help you focus on financially resilient companies.
• If capital protection matters more than chasing headlines, narrow your search to a 11 resilient stocks with low risk scores that screens for businesses with lower overall risk scores.
• For investors hunting for quality at a reasonable price, a 34 high quality undervalued stocks can surface stocks where fundamentals and valuation filters line up cleanly.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com